These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33693297)

  • 1. Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study)　- Protocol of a Multicenter Randomized Control Trial.
    Akagi S; Dohi Y; Ishikawa K; Kubota K; Horimoto K; Yagi S; Hirata T; Yamamoto E; Ito H; Nakamura K
    Circ Rep; 2021 Jan; 3(2):105-109. PubMed ID: 33693297
    [No Abstract]   [Full Text] [Related]  

  • 2. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
    Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
    Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.
    Grünig E; Jansa P; Fan F; Hauser JA; Pannaux M; Morganti A; Rofael H; Chin KM
    J Am Coll Cardiol; 2024 Jan; 83(4):473-484. PubMed ID: 38267108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
    Chin KM; Sitbon O; Doelberg M; Feldman J; Gibbs JSR; Grünig E; Hoeper MM; Martin N; Mathai SC; McLaughlin VV; Perchenet L; Poch D; Saggar R; Simonneau G; Galiè N
    J Am Coll Cardiol; 2021 Oct; 78(14):1393-1403. PubMed ID: 34593120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Triple combination therapy with macitentan, riociguat, and selexipag in a patient with idiopathic pulmonary arterial hypertension (functional class III)].
    Proshkina AA; Tsareva NA; Nekludova GV; Avdeev SN
    Kardiologiia; 2021 Oct; 61(10):104-107. PubMed ID: 34763645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension.
    Sulica R; Sangli S; Chakravarti A; Steiger D
    Pulm Circ; 2019; 9(1):2045894019826944. PubMed ID: 30638432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension.
    Hu X; Yuan P; Chen J; Wang S; Zhao H; Wei Y; Fu J; Chen F; Ruan H; Zhang W; Zhou Y; Wang Q; Xu X; Feng K; Guo J; Gong S; Zhang R; Zhao Q; Wang L
    Clin Cardiol; 2024 Feb; 47(2):e24245. PubMed ID: 38402556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
    Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
    Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
    Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
    BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia].
    Shmalts AA; Gorbachevsky SV
    Ter Arkh; 2020 Dec; 92(12):80-85. PubMed ID: 33720578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension.
    Dong W; Zhang Z; Chu M; Gu P; Hu M; Liu L; Huang J; Zhang R
    Front Pharmacol; 2023; 14():1122866. PubMed ID: 37637431
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag:  a case report.
    Lattanzio M; Ferrari M; Martini S; Ceriani F; Imporzani A; Marino F; De Ponti R; Cosentino M
    J Med Case Rep; 2022 Oct; 16(1):385. PubMed ID: 36258237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
    Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
    Kim NH; Hemnes AR; Chakinala MM; Highland KB; Chin KM; McLaughlin V; Zhao C; Narayan V; Farber HW
    J Heart Lung Transplant; 2021 Apr; 40(4):279-288. PubMed ID: 33526303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension.
    Mercurio V; Bianco A; Campi G; Cuomo A; Diab N; Mancini A; Parrella P; Petretta M; Hassoun PM; Bonaduce D
    Curr Med Chem; 2019; 26(16):2844-2864. PubMed ID: 29421995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension.
    Ornstová E; Tužil J; Chadimová K; Mlčoch T; Doležal T
    Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1269-1275. PubMed ID: 36121156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.
    Coghlan JG; Channick R; Chin K; Di Scala L; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin V; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Gaine S
    Am J Cardiovasc Drugs; 2018 Feb; 18(1):37-47. PubMed ID: 29307087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT).
    Aldalaan AM; Saleemi SA; Weheba I; Abdelsayed A; Aleid MM; Alzubi F; Zaytoun H; Alharbi N
    Pulm Circ; 2022 Apr; 12(2):e12083. PubMed ID: 35514768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the management of pulmonary arterial hypertension.
    Tsai H; Sung YK; de Jesus Perez V
    F1000Res; 2016; 5():2755. PubMed ID: 27990270
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.